AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 38.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,002 shares of the company’s stock after selling 7,487 shares during the period. Freedom Investment Management Inc.’s holdings in AstraZeneca were worth $935,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZN. CANADA LIFE ASSURANCE Co lifted its stake in AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of AstraZeneca during the 1st quarter worth $914,000. B. Riley Wealth Advisors Inc. grew its stake in shares of AstraZeneca by 36.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 23,504 shares of the company’s stock worth $1,592,000 after purchasing an additional 6,224 shares in the last quarter. Tidal Investments LLC purchased a new position in AstraZeneca in the first quarter valued at $327,000. Finally, Atria Investments Inc raised its stake in AstraZeneca by 0.7% in the first quarter. Atria Investments Inc now owns 85,255 shares of the company’s stock valued at $5,776,000 after buying an additional 629 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Finally, TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $67.20 on Friday. The business’s 50-day moving average price is $72.48 and its 200 day moving average price is $77.50. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market cap of $208.36 billion, a P/E ratio of 32.15, a P/E/G ratio of 1.23 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business posted $0.87 EPS. The company’s revenue was up 18.0% on a year-over-year basis. On average, equities research analysts expect that AstraZeneca PLC will post 4.1 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.